Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome
The COVID-19 pandemics has caused the death of almost six million people worldwide. In order to establish collective immunity, the first vaccines that were approved in Germany were the vector virus-based vaccine Vaxzevria and the mRNA vaccines Comirnaty and Spikevax, respectively. As it was reported...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/2/333 |
| _version_ | 1827652291421798400 |
|---|---|
| author | Christoph Thurm Annegret Reinhold Katrin Borucki Sascha Kahlfuss Eugen Feist Jens Schreiber Dirk Reinhold Burkhart Schraven |
| author_facet | Christoph Thurm Annegret Reinhold Katrin Borucki Sascha Kahlfuss Eugen Feist Jens Schreiber Dirk Reinhold Burkhart Schraven |
| author_sort | Christoph Thurm |
| collection | DOAJ |
| description | The COVID-19 pandemics has caused the death of almost six million people worldwide. In order to establish collective immunity, the first vaccines that were approved in Germany were the vector virus-based vaccine Vaxzevria and the mRNA vaccines Comirnaty and Spikevax, respectively. As it was reported that SARS-CoV-2 can trigger autoimmunity, it is of significant interest to investigate whether COVID-19 vaccines evoke the formation of autoantibodies and subsequent autoimmunity. Here, we analyzed immune responses after different vaccination regimens (mRNA/mRNA, Vector/Vector or Vector/mRNA) with respect to anti-SARS-CoV-2-specific immunity and the development of autoantibodies well known for their appearance in distinct autoimmune diseases. We found that anti-SARS-CoV-2 antibody levels were 90% lower after Vector/Vector vaccination compared to the other vaccinations and that Vector/mRNA vaccination was more effective than mRNA/mRNA vaccination in terms of IgM and IgA responses. However, until 4 months after booster vaccination we only detected increases in autoantibodies in participants with already pre-existing autoantibodies whereas vaccinees showing no autoantibody formation before vaccination did not respond with sustained autoantibody production. Taken together, our study suggests that all used COVID-19 vaccines do not significantly foster the appearance of autoantibodies commonly associated with lupus erythematodes, rheumatoid arthritis, Celiac disease and antiphospholipid-syndrome but provide immunity to SARS-CoV-2. |
| first_indexed | 2024-03-09T20:53:26Z |
| format | Article |
| id | doaj.art-4ef895997a664dca97ea090c4d0ffcdc |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T20:53:26Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-4ef895997a664dca97ea090c4d0ffcdc2023-11-23T22:27:22ZengMDPI AGVaccines2076-393X2022-02-0110233310.3390/vaccines10020333Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid SyndromeChristoph Thurm0Annegret Reinhold1Katrin Borucki2Sascha Kahlfuss3Eugen Feist4Jens Schreiber5Dirk Reinhold6Burkhart Schraven7Institute of Molecular and Clinical Immunology, Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyInstitute of Molecular and Clinical Immunology, Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyInstitute of Clinical Chemistry and Pathobiochemistry, Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyInstitute of Molecular and Clinical Immunology, Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyHealth Campus Immunology, Infectiology and Inflammation (GC-I3), Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyHealth Campus Immunology, Infectiology and Inflammation (GC-I3), Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyInstitute of Molecular and Clinical Immunology, Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyInstitute of Molecular and Clinical Immunology, Medical Faculty, Otto-von-Guericke-University, 39120 Magdeburg, GermanyThe COVID-19 pandemics has caused the death of almost six million people worldwide. In order to establish collective immunity, the first vaccines that were approved in Germany were the vector virus-based vaccine Vaxzevria and the mRNA vaccines Comirnaty and Spikevax, respectively. As it was reported that SARS-CoV-2 can trigger autoimmunity, it is of significant interest to investigate whether COVID-19 vaccines evoke the formation of autoantibodies and subsequent autoimmunity. Here, we analyzed immune responses after different vaccination regimens (mRNA/mRNA, Vector/Vector or Vector/mRNA) with respect to anti-SARS-CoV-2-specific immunity and the development of autoantibodies well known for their appearance in distinct autoimmune diseases. We found that anti-SARS-CoV-2 antibody levels were 90% lower after Vector/Vector vaccination compared to the other vaccinations and that Vector/mRNA vaccination was more effective than mRNA/mRNA vaccination in terms of IgM and IgA responses. However, until 4 months after booster vaccination we only detected increases in autoantibodies in participants with already pre-existing autoantibodies whereas vaccinees showing no autoantibody formation before vaccination did not respond with sustained autoantibody production. Taken together, our study suggests that all used COVID-19 vaccines do not significantly foster the appearance of autoantibodies commonly associated with lupus erythematodes, rheumatoid arthritis, Celiac disease and antiphospholipid-syndrome but provide immunity to SARS-CoV-2.https://www.mdpi.com/2076-393X/10/2/333SARS-CoV-2COVID-19COVID-19 vaccinationautoimmunityantiphospholipid syndromeCCP |
| spellingShingle | Christoph Thurm Annegret Reinhold Katrin Borucki Sascha Kahlfuss Eugen Feist Jens Schreiber Dirk Reinhold Burkhart Schraven Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome Vaccines SARS-CoV-2 COVID-19 COVID-19 vaccination autoimmunity antiphospholipid syndrome CCP |
| title | Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome |
| title_full | Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome |
| title_fullStr | Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome |
| title_full_unstemmed | Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome |
| title_short | Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome |
| title_sort | homologous and heterologous anti covid 19 vaccination does not induce new onset formation of autoantibodies typically accompanying lupus erythematodes rheumatoid arthritis celiac disease and antiphospholipid syndrome |
| topic | SARS-CoV-2 COVID-19 COVID-19 vaccination autoimmunity antiphospholipid syndrome CCP |
| url | https://www.mdpi.com/2076-393X/10/2/333 |
| work_keys_str_mv | AT christophthurm homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome AT annegretreinhold homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome AT katrinborucki homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome AT saschakahlfuss homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome AT eugenfeist homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome AT jensschreiber homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome AT dirkreinhold homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome AT burkhartschraven homologousandheterologousanticovid19vaccinationdoesnotinducenewonsetformationofautoantibodiestypicallyaccompanyinglupuserythematodesrheumatoidarthritisceliacdiseaseandantiphospholipidsyndrome |